Camptothecin is a widely used anti-tumor drug that specifically inhibits DNA topoisomerase I. It is believed that topoisomerase I participates in the process of transcription by relaxing torsional stress induced in the duplex DNA by the elongating RNA polymerase. We have assessed the effects of camptothecin on RNA polymerase II transcription from the dihydrofolate reductase (DHFR) gene in Chinese hamster ovary (CHO) cells. Using in vivo [ 3 H]uridine pulse labeling and in vitro nuclear run-on techniques to estimate relative rates of transcription, it was found that camptothecin stimulated RNA synthesis from promoter-proximal sequences of the DHFR gene, while transcription from promoter-distal sequences was reduced. Furthermore, camptothecin caused a significant accumulation of RNA polymerases in the 5'-end of the DHFR gene. The effect of camptothecin on transcription was reversible, resulting in a wave of RNA synthesis recovery in a 5' to 3' direction through the DHFR gene following a chase with camptothecin-free medium. We conclude that camptothecin stimulates initiation but inhibits elongation of the RNA polymerase II transcribed DHFR gene.
Introduction
Camptothecin is a plant alkaloid possessing a broad spectrum of anti-tumor activity (1). Treatment of cells with camptothecin has been shown to result in the inhibition of the synthesis of both DNA (2) and RNA (3) (4) (5) as well as the induction of the tumor suppressor protein p53 (6) and the fragmentation of chromosomal DNA (7) . Camptothecin also selectively kills cells in the S-phase (8) and arrests cells in the G2 phase of the cell cycle (9) . It is well established that the underlying mechanism responsible for these cellular effects of camptothecin is the inhibition of DNA topoisomerase I (10, 11) .
The principal function of DNA topoisomerase I is to relax DNA torsional stress induced by DNA replication fork movement and by transcriptional elongation (for reviews see 1,12). The mechanism of relaxation has been shown to involve the formation of a transient DNA single-strand break through which the other DNA strand is passed, followed by the rejoining of the transient break (12) (13) (14) . Camptothecin specifically interferes with the rejoining step in the topoisomerase reaction which results in the trapping of the topoisomerase I enzyme in a reversible cleavable complex (10, 11) . It is thought that this trapped topoisomerase complex is a barrier for RNA polymerase elongation (15) . It has been shown that the It has been shown that topoisomerase I is involved in both the initiation (17,18) and elongation (19-21) of RNA polymerase II transcribed genes. The aim of this study was to assess the effect of camptothecin on transcription from the polymerase II transcribed dihydrofolate reductase (DHFR*) gene. Transcription from three different regions of the DHFR gene in Chinese hamster ovary (CHO) B11 cells was assessed both in vivo by [ 3 H]uridine pulse labeling followed by DNA filter excess hybridization, and in vitro by the nuclear run-on technique. Results show that in cells treated with camptothecin, transcription was affected differentially throughout the DHFR gene. While transcription from promoter-distal sequences of the gene was reduced, transcription from the 5'-end of the DHFR gene was stimulated in the presence of camptothecin.
Materials and methods

Cell culture
The methotrexate-resistant Chinese hamster cell line, CHO Kl Bll [0.5], containing an ~50-fold amplification of the DHFR gene (22) , was plated at a density of 1.5 X 10 6 cells per 60 cm 2 culture dish in minimal essential medium (MEM) supplemented with 10% dialyzed fetal bovine serum, 2 mM glutamine, 1 X non-essential amino acids, 100 IU penicillin, 100 u.g/ml streptomycin, 0.25 |ig/ml amphotencin and 5000 Bq/ml [methyl-
3 H]thymidine (nuclear run-on experiments) or 150 Bq/ml [methyll4 C]thymidine (Amersham) ([ 3 H]uridine-labeling experiments). Methotrexate (Calbiochem Corp, La Jolla, CA) was included in the medium at a final concentration of 0.55 |iM to select for cells maintaining the amplified DHFR gene. The medium was removed 24 h after seeding the cells and the cells were rinsed with PBS. The cells were then supplied with a medium containing 0.1% fetal bovine serum but lacking labeled nucleotides After 4 days of incubation in the low serum medium (serum starvation), the cells were stimulated by exchanging the medium with medium containing 15% fetal bovine serum. The camptothecin experiments were performed 15 h after the serum addition to allow for maximal transcription of the DHFR gene (23, 24) .
In vivo transcription
The measurement of in vivo synthesis of nascent RNA was performed as previously described (24) except for the labeling period which was shortened to 15 min. CHO Bll cells were either washed twice in PBS and supplied with camptothecin-free media (chase experiments) or left in 0.8 ml of medium containing 20 |iM camptothecin. RNA labeling took place in 1 ml of labeling solution consisting of 800 uJ conditioned medium (with or without camptothecin) and 200 |il of an aqueous solution containing 200 (iCi (7.4 MBq) of H]uridine (Amersham). After the completion of RNA labeling (15 min), the cells were put on ice and rinsed several times with icecold PBS. The RNA was then partially hydrolyzed in cold alkali to produce RNA fragments in the size range of 200 bases (25) . These RNA fragments were hybridized at 65°C for 48 h to 2-4 ng of denatured and sonicated DNA probes immobilized on Hybond N+ membranes (Amersham). Following a stringency wash at 65°C in O.lxSSPE and 0.1% SDS for 60 min, the membranes were dried and 3 H was determined by scintillation counting. The values obtained were corrected for the number of cells present in each sample which was estimated from the relative DNA content measured from counting I4 C following the DNase I digestion step in the RNA extraction protocol (24) .
In vitro nuclear run-on transcription
The nuclear run-on procedure was performed as previously described (24) . Nuclei were isolated from -I0 7 cells and heterogeneous nuclear RNA was labeled in vitro in the absence of camptothecin with 32 P-labeled UTP for 15 min at 30°C. RNA was then isolated, partially hydrolyzed in cold alkali (25) and hybridized at 65°C for 48 h to 2-A |ig of DNA probes immobilized on Hybond N+ membranes. Membranes were stringency washed at 65°C in 0.1 X SSPE and 0.1% SDS for 60 min. Autoradiographs were scanned using a scanning densitometer (Helena Laboratories), and peak values were corrected for cell input by measuring the tritium count of isolated nuclei prior to the run-on protocol (24) . -30% of that in untreated control cells as measured by liquid scintillation counting of a small aliquot of isolated total RNA ( Figure 3 ). This inhibitory effect on total RNA synthesis by camptothecin is consistent with results obtained by others (3, 5) . When studying the effect of camptothecin on the RNA polymerase II transcribing DHFR gene, it was found that transcription was differentially affected throughout the gene. RNA synthesis was enhanced in the 5'-end of the DHFR gene to -150% of that of untreated control cells, while RNA synthesis was severely inhibited in the middle portion and the 3'-end to 20% and 10% of that of untreated controls, respectively. RNA synthesis from the 3'-half of the rRNA transcriptional unit was virtually abolished in the presence of camptothecin, a result which supports earlier findings (16).
Results
Camptothecin enhances transcription in the 5'-end of the DHFR gene in vivo
Nuclear run-on technique reveals a dramatic increase in transcription signal from the 5'-end of the DHFR gene
The effect of camptothecin on DHFR transcription was also evaluated using the nuclear run-on technique. In this technique, the in vivo distribution of RNA polymerases on a particular gene is scored by allowing engaged RNA polymerases to elongate in vitro in the presence of [ 32 P]UTP (25, 26) . The results obtained support the results from the uridine-labeling experiments in that the DHFR RNA synthesis was enhanced in the 5'-end ( Figure 4A,B) . However, the enhancement of the in vitro nuclear run-on labeling was much greater. In fact, the [ 32 P]UTP-incorporation in the run-on transcripts from the 5'-end was 10-15 times higher in nuclei from camptothecintreated cells than in untreated control cells. This is to be compared to the 50% increase of transcription in the equivalent experiment using the in vivo uridine-labeling technique (see Figure 3 ). Another discrepancy between the results obtained using the two different techniques was that the marked inhibi- 
was not that obvious when using the in vitro nuclear run-on technique. However, synthesis of rRNA was severely inhibited by camptothecin when measured with both transcription assays.
Recovery of transcription bv the removal of camptothecin
In the next set of experiments, we wanted to address the question of whether the effects of camptothecin on transcription were reversible. Cells were treated with 20 yiM camptothecin for 30 min at 37°C, and nascent RNA was [ 3 H]uridinelabeled in vivo for 15 min in camptothecin-free media (chase 0-15 min). In addition, some cells were allowed to incubate in drug-free media for 15 min prior to the uridine-labeling of the RNA in drug-free media (chase 15-30 min) (Figure 1) .
The results show that a chase of camptothecin-treated cells with drug-free media only partially restored synthesis of total RNA from -30% to -50-60% of that synthesized in untreated control cells ( Figure 5 ). The same was true for rRNA synthesis where in vivo [ transcription from the 5'-end of the DHFR gene revealed that transcription remained elevated at levels of -50% of that of controls even after 15-30 min of incubation in drug-free media. Transcription from the middle portion of the DHFR gene rebounded from -20% to -60% during a 15 min chase and to control levels during a 15-30 min chase. At the 3'-end of the DHFR gene, the transcription showed no signs of recovery during a 0-15 min chase but transcription was fully recovered after a 15-30 min incubation in drug-free media.
Discussion
The effect of the anti-cancer drug camptothecin on RNA polymerase II transcription of the DHFR gene was assessed using both in vivo [ 3 H]uridine-labeling and in vitro nuclear run-ons to study nascent RNA synthesis. Although both assays showed that RNA synthesis was enhanced by camptothecin in promoter-proximal regions while reduced in promoter-distal regions, the two transcription assays gave quantitatively different results. While the in vivo pulse-labeling assay snowed a 1.5-fold enhancement of promoter-proximal transcription by camptothecin, the in vitro run-on assay revealed a 10-to 15-fold increase in this region (compare Figures 3 and 4B) . Furthermore, transcription from promoter-distal regions appeared more severely inhibited by camptothecin when using the in vivo pulse-labeling technique in comparison to the in vitro nuclear run-on technique (compare Figures 3 and 4B) .
Discrepancies in the results obtained from in vivo [
3 H]uridine pulse-labeling and in vitro nuclear run-on transcription have been reported before (27) . It is believed that the two assays measure different aspects of transcription. While the in vivo undine pulse-labeling technique is thought to reflect transcription elongation in intact cells, the in vitro nuclear run-on technique merely reflects the abundance of RNA polymerases within a specific gene. Thus, the nuclear run-on assay is not necessarily a good measure of rates of transcription in cells (27) . However, this technique is still informative on the abundance and location of polymerases within a gene whether they are elongating or not. The release of blocked polymerases in the run-on assay may result from the preparation of nuclei which introduces DNA nicks and modifies the interactions of proteins with DNA.
Assuming that the in vitro run-on technique reflects the abundance of RNA polymerases in a particular region and that the in vivo pulse-labeling technique reflects the rate of RNA synthesis in vivo (27) , we conclude that a large number of RNA polymerases accumulated in the promoter-proximal region of the DHFR gene during the camptothecin treatment ( Figure  6B ). In support of this, we have recently obtained results using a psoralen photocross-linking approach suggesting that the accessibility of the DNA in the promoter region of the DHFR gene is reduced following camptothecin treatment (unpublished results). Furthermore, the majority of these polymerases were not capable of elongating in vivo since the huge increase in the in vitro run-on signal (10 to 15-fold) was not matched by a comparable increase in the in vivo pulse-labeling (1.5-fold). These results suggest that camptothecin enhances transcriptional initiation but that the elongation of the polymerases is blocked shortly after initiation, most likely by a topoisomerase I complex trapped by camptothecin on the transcribed strand.
Following the removal of camptothecin we found that synthesis of DHFR RNA recovered in a wave that progressed in a 5' to 3' direction ( Figure 6C ). The rate of RNA synthesis from the middle portion of the gene was approaching control levels within the first 15 min of the chase, while little recovery was detected in the 3'-end until after an additional 15 min of chase ( Figure 6D ). Interestingly, the polymerases that had accumulated at the 5'-end during drug treatment did not appear to translocate down the gene all at once following drug removal. Regarding the kinetics of RNA synthesis recovery throughout the gene, it has been estimated that the rate of elongation in vivo for mammalian RNA polymerases is -30 nucleotides per second (28) . That means that it would take an RNA polymerase -17 min to traverse the 30 kb long DHFR gene from start to finish. We found in our study that the synthesis of RNA from the 3'-end of the DHFR gene resumed control levels following a 15-30 min chase in camptothecinfree media. This result is in excellent accord with the estimated elongation rate of the RNA polymerase (28) and suggests that RNA synthesis following drug removal is either carried out by newly initiated polymerases or by polymerases that accumulated at the 5'-end of the DHFR gene during the camptothecin treatment.
What are the mechanisms for the enhanced initiation of the DHFR gene by camptothecin? The role of DNA topoisomerase I during the transcription process is to relax the torsional strain induced by the elongating RNA polymerase (16, 21, 29) . Inhibition of topoisomerase I by camptothecin may result in the escape of transcription-induced torsional tension. Although transcriptional elongation is limited in the presence of camptothecin (15, 16 , this study), some transcription-induced supercoiling may still be generated both in the wake of and ahead of the polymerase (29) . Since the DHFR promoter region is located between two divergently transcribing genes (30), the inhibition of topoisomerase I may lead to an accumulation of transcription-generated negative torsional tension in this region. Negative torsional tension has been found to enhance the early stages of transcription both in vitro (31) (32) (33) and in vivo (34) (35) (36) (37) . We have previously found evidence for the presence of negative torsional tension in the promoter region of the DHFR gene in both human (38) and hamster cells (24) .
In accordance with results from a previous study (16), camptothecin was found to severely reduce the rate of RNA synthesis from promoter-distal regions of the RNA polymerase I transcribed ribosomal RNA genes (Figures 3 and 4) . However, the results obtained for the RNA polymerase II transcribed DHFR gene following camptothecin treatment differ somewhat from the results obtained on the transcription of the ribosomal genes. Our nuclear run-on data from camptothecin-treated cells suggest a much greater relative accumulation of RNA polymerases at the 5'-end of the DHFR gene (10 to 15-fold) than that reported for the 5'-end of the ribosomal genes (1.4-fold) (16). Perhaps the high transcriptional activity of the ribosomal genes in dividing cells does not allow for any additional polymerases to accumulate onto the DNA template even in the presence of camptothecin. In fact, a higher relative accumulation of RNA polymerases at the 5'-end of the ribosomal genes by camptothecin has been observed when confluent cells were used (16).
In conclusion, camptothecin was found to enhance the rate of transcriptional initiation while inhibiting the rate of elongation by RNA polymerase II in the DHFR gene. This resulted in the accumulation of RNA polymerases in the 5'-region of the DHFR gene. Following drug removal, the RNA synthesis returned in a 5' to 3' direction. A possible application of a protocol of camptothecin treatment and reversal is that it could be used in studies where a synchronized wave of transcription from the 5'-end to the 3-end is desired. Of interest would be to study the phenomena of transcription-coupled DNA repair in different parts of a gene in which transcription proceeds in such a synchronized manner. In addition, further studies will determine how important the effects on RNA synthesis are for the anti-tumor activity of camptothecin.
